Objective-Cyclophilin A (CyPA, encoded by Ppia) is a proinflammatory protein secreted in response to oxidative stress in mice and humans. We recently demonstrated that CyPA increased angiotensin II (Ang II)-induced reactive oxygen species (ROS) production in the aortas of apolipoprotein E (Apoe) Ϫ/Ϫ mice. In this study, we sought to evaluate the role of CyPA in Ang II-induced cardiac hypertrophy. Methods and Results-Cardiac hypertrophy was not significantly different between Ppia ϩ/ϩ and Ppia Ϫ/Ϫ mice infused with Ang II (1000 ng/min per kg for 4 weeks). Therefore, we investigated the effect of CyPA under conditions of high ROS and inflammation using the Apoe Ϫ/Ϫ mice. In contrast to Apoe Ϫ/Ϫ mice, Apoe Ϫ/Ϫ Ppia Ϫ/Ϫ mice exhibited significantly less Ang II-induced cardiac hypertrophy. Bone marrow cell transplantation showed that CyPA in cells intrinsic to the heart plays an important role in the cardiac hypertrophic response. Ang II-induced ROS production, cardiac fibroblast proliferation, and cardiac fibroblast migration were markedly decreased in Apoe Ϫ/Ϫ Ppia Ϫ/Ϫ cardiac fibroblasts. Furthermore, CyPA directly induced the hypertrophy of cultured neonatal cardiac myocytes. Conclusion-CyPA is required for Ang II-mediated cardiac hypertrophy by directly potentiating ROS production, stimulating the proliferation and migration of cardiac fibroblasts, and promoting cardiac myocyte hypertrophy. Key Words: cardiac hypertrophy Ⅲ cardiac remodeling Ⅲ oxidative stress C ardiac hypertrophy is a fundamental response of cardiac cells to common clinical disorders, such as arterial hypertension, valvular heart disease, myocardial infarction, cardiomyopathy, and congenital heart disease. 1 Emerging data reveal that the communication between cardiac fibroblasts and myocytes plays a critical role in cell-cell signaling in the heart, and it is implicated in the process of cardiac remodeling and overall heart function during development and cardiopathology. [2] [3] [4] [5] There are numerous lines of evidence indicating that cardiac fibroblasts and myocytes release into their local microenvironment proteins that regulate neighboring cells via paracrine mechanisms. 2-5 Although multiple factors have been implicated in this intercellular crosstalk, the discovery of new hypertrophic players and a better understanding of the underlying mechanisms hold the key to successful therapy of hypertrophic heart disease.
C ardiac hypertrophy is a fundamental response of cardiac cells to common clinical disorders, such as arterial hypertension, valvular heart disease, myocardial infarction, cardiomyopathy, and congenital heart disease. 1 Emerging data reveal that the communication between cardiac fibroblasts and myocytes plays a critical role in cell-cell signaling in the heart, and it is implicated in the process of cardiac remodeling and overall heart function during development and cardiopathology. [2] [3] [4] [5] There are numerous lines of evidence indicating that cardiac fibroblasts and myocytes release into their local microenvironment proteins that regulate neighboring cells via paracrine mechanisms. [2] [3] [4] [5] Although multiple factors have been implicated in this intercellular crosstalk, the discovery of new hypertrophic players and a better understanding of the underlying mechanisms hold the key to successful therapy of hypertrophic heart disease.
Cyclophilin A (CyPA, encoded by Ppia) was originally found as a binding partner of cyclosporine A. 6 Intracellular CyPA is a chaperone protein that has several functions, including peptidyl-prolyl isomerase activity and protein trafficking, such as nuclear translocation of ERK1/2 7 and apoptosis-inducing factor. 8 We and others have provided evidence that CyPA is secreted in response to reactive oxygen species (ROS) from vascular smooth muscle cells 9 and rat neonatal cardiac myocytes. 10 Moreover, we have shown the involvement of CyPA in angiotensin II (Ang II)-induced aortic aneurysms and oxidative stress. 11, 12 Ang II plays a key role in many physiological and pathological processes in cardiac cells, including cardiac hypertrophy. 13 Therefore, understanding the molecular mechanisms responsible for Ang II-mediated myocardial pathophysiology will be critical to developing new therapies for cardiac dysfunction. 14 One important mechanism now recognized to be involved in Ang II-induced cardiac hypertrophy is ROS production, 15, 16 but the precise mechanism by which ROS cause hypertrophy remains unknown. Our recent study provides strong mechanistic evidence of synergy between CyPA and Ang II to increase ROS generation. 11 Because ROS stimulate myocardial hypertrophy, matrix remodeling, and cellular dysfunction, 17 we tested the hypothesis that CyPA enhances Ang II-induced cardiac ROS production and therefore cardiac hypertrophy.
Methods
An expanded Supplemental Methods section is available online at http://atvb.ahajournals.org.
Analysis of Cardiac Hypertrophy
Ang II-infused models were used to assess the effect of CyPA deficiency on cardiac hypertrophy. 18 Five-to 6-week-old male mice on a normal chow diet were infused with 1000 ng/min per kg Ang II (MP Biomedicals, Solon, OH) or saline vehicle for 4 weeks. Ang II was dissolved in sterile saline and infused using Alzet osmotic pumps (model 2004, Durect Corp, Cupertino, CA). Mice were anesthetized with an intraperitoneal injection of ketamine (80 mg/kg) and xylazine (5 mg/kg). Pumps were placed into the subcutaneous space of anesthetized mice through a small incision in the back of the neck that was closed with suture. After 4 weeks of Ang II infusion, the animals were again anesthetized with ketamine (80 mg/kg) and xylazine (5 mg/kg). The heart tissue was perfused with calcium-and magnesium-free phosphate-buffered saline (PBS) and then fixed with phosphate-buffered 10% formalin solution and subsequently prepared for histological analysis as previously described. 19 Heart weight was measured, and the ratio of heart weight to body weight (BW) was calculated to determine an index of cardiac hypertrophy. Five sections were obtained from each heart and mounted on slides and stained with Masson's trichrome or hematoxylin/eosin (H&E). To evaluate the perivascular fibrosis, short-axis images of coronary arteries were scanned at ϫ200 magnification. The area of perivascular fibrosis (the ratio of the fibrosis area surrounding the vessel to the total vessel area) was calculated. To evaluate the extent of cardiac myocyte hypertrophy, cross-sectional images of cardiac myocytes were scanned at ϫ400 magnification. Approximately 10 cross-sections of cardiac myocytes were analyzed in each heart. Average values for each heart were used for analysis.
Bone Marrow Transplantation
Bone marrow transplantation was performed as described. 20 Briefly, recipient mice were lethally irradiated and received an intravenous injection of 5ϫ10 6 donor bone marrow cells suspended in 100 L of PBS with 2% fetal bovine serum. After transplantation, the mice were placed on a regular chow diet for 6 weeks followed by infusion of 1000 ng/kg per minute Ang II for 4 weeks. Transgenic mice ubiquitously expressing green fluorescent protein (GFP) were obtained from the Jackson Laboratory (Bar Harbor, ME). The chimeric rate assessed by GFP ϩ cells in the peripheral blood was more than 99% by fluorescence-activated cell sorter analysis (FACSCantoII, Becton Dickinson, San Jose, CA).
ROS Analysis
The evaluation of ROS production in response to Ang II was performed as described before. 21 After treatment with Ang II (1 mol/L), cardiac fibroblasts were washed with PBS and loaded with 2,7-dichlorofluoresceine diacetate (5 mol/L; Molecular Probes) for 30 minutes. Hearts were perfused with PBS (pH 7.4) at 100 mm Hg for 5 minutes at 4°C. Heart tissue was harvested and embedded in OCT (Tissue-Tek, Miles Inc., Elkhart, IL) and snapfrozen. Dihydroethidine hydrochloride (5 mol/L, Molecular Probes) was topically applied to the freshly cut frozen heart sections (10 m) for 30 minutes at 37°C. Dichlorofluorescein (DCF) and dihydroethidium fluorescence was revealed by confocal microscopy (Olympus, Fluoview). 22 A lucigenin assay was performed as previously described, with some modifications. 23 Briefly, control cells or cells treated with Ang II for 4 hours were harvested and pelleted by centrifugation (1200 rpm, 4°C, 5 minutes). To start the assay, cells were resuspended in Hanks' balanced salt solution (Cellegro) containing lucigenin (final concentration, 500 mol/L). Photon emission was measured every 15 seconds for 20 minutes in a luminometer (Wallac Plate Reader, model 1420). A buffer blank (Ͻ5% of the cell signal) was subtracted from each reading before transformation of the data.
[ 3 H]Leucine Incorporation Study
The effect of conditioned medium (CM) from Ang II-stimulated cardiac fibroblasts for protein synthesis in cardiac myocytes was 24 Briefly, neonatal rat cardiac myocytes were plated at a density of 250,000 cells/well in 12-well plates and maintained in Dulbecco's modified Eagle's medium supplemented with insulin, transferrin, and selenium, 5% horse serum, 5% fetal calf serum, 50 U/mL penicillin, and 50 g/mL streptomycin for 24 hours. The cells were then starved in serum-free Dulbecco's modified Eagle's medium for 48 hours. Cardiac myocytes were stimulated with cardiac fibroblastderived CM for 24 hours following incubation with [ 3 H]leucine (2 Ci/mL) for 24 hours. To precipitate proteins, ice-cold 10% trichloroacetic acid was added to the wells. After 30 minutes of incubation on ice, the myocytes were lysed with 0.5 N NaOH and incubated for 10 minutes on ice. All samples were mixed with scintillation cocktail (Biosafe-II) before counting.
Statistical Analysis
Quantitative results are expressed as meanϮSD. Comparisons of parameters among 2 groups were made by the unpaired Student t test. Comparisons of parameters among Ͼ2 groups were made by 1-way ANOVA, and comparisons of different parameters between the 2 genotypes were made by 2-way analysis of variance (ANOVA), followed by a post hoc analysis using the Bonferroni test. Statistical significance was evaluated with StatView (StatView 5.0, SAS Institute Inc, Cary, NC). A value of PϽ0.05 was considered to be statistically significant.
Results

CyPA Augments Ang II-Induced Cardiac Hypertrophy In Vivo
To define the role of CyPA in cardiac hypertrophy, we studied the Ppia Ϫ/Ϫ (knockout) and wild-type (WT) mice following Ang II infusion for 4 weeks. Ang II significantly increased heart weight/BW in both Ppia Ϫ/Ϫ and WT mice ( Figure 1A and 1C) . However, there were no significant differences in heart weight/BW ( Figure 1A and 1C) , systolic blood pressure, or interventricular septum thickness (Supplemental Table I ) between Ppia Ϫ/Ϫ and WT mice before or after Ang II treatment. Although there was an apparent increase in echo-estimated left ventricle (LV) mass in the WT compared with Ppia Ϫ/Ϫ , when gravimetric heart was normalized to the BW, the relative increase in heart weight/BW did not differ significantly (1.25-fold versus 1.20-fold).
Because CyPA is a proinflammatory cytokine secreted in response to oxidative stress, we hypothesized that the role of CyPA in cardiac hypertrophy would require a situation in which there was increased ROS generation or inflammation. Previously, it was demonstrated that the hearts of apolipoprotein E (Apoe) Ϫ/Ϫ mice exhibit increased ROS production. 11 Because we showed that ROS generation stimulates secretion of CyPA from vascular smooth muscle cells, we compared the secretion of CyPA from WT and Apoe Ϫ/Ϫ cardiac fibroblasts in response to Ang II. Secretion of CyPA was barely detected in conditioned media (CM) from WT fibroblasts (Supplemental Figure I) . In contrast, there was abundant CyPA secretion from Ang II-treated Apoe Ϫ/Ϫ cardiac fibroblasts. We attempted similar experiments in cultured adult cardiac myocytes. However, substantial cell death ensued on culture in the required serum-free medium.
The above data suggest that Apoe Ϫ/Ϫ mice would provide an ideal model by which to study the role of CyPA in Ang II-induced cardiac hypertrophy. Consistent with previous findings, 18 we showed that Ang II infusion for 4 weeks significantly increased cardiac hypertrophy in Apoe Ϫ/Ϫ mice ( Figure 1B and  1D ). Despite equal increases in blood pressure (Supplemental Figure 2D ). These data suggest that CyPA contributes to cardiac hypertrophy and perivascular fibrosis in Apoe Ϫ/Ϫ mice.
CyPA Deficiency Prevents Ang II-Induced ROS Production in Cardiac Tissue
Because ROS are key mediators of Ang II action, we next investigated whether CyPA altered the redox state of the heart after Ang II treatment. Heart sections were incubated with dihydroethidium, which in the presence of superoxide anions is transformed to fluorescent oxyethidium. In the saline-infused heart, ROS production (red fluorescence) was low in both Apoe Ϫ/Ϫ and Apoe Figure 3A , 3B, and 3E). After Ang II treatment, in the whole heart, oxyethidium fluorescence was Ϸ2-fold greater in Apoe Ϫ/Ϫ mice compared with Apoe Figure 3C , 3D, and 3E). In the perivascular area of Apoe Ϫ/Ϫ mice, ROS production was increased by 4-fold after Ang II-treatment ( Figure 3C and 3F) . In contrast, in Apoe Ϫ/Ϫ Ppia Ϫ/Ϫ mice, the perivascular increase in ROS was markedly reduced (Figure 3D and 3F ). These data suggest that CyPA is a key determinant for Ang II-mediated ROS production.
Cardiac-Derived CyPA Promotes Recruitment of Bone Marrow-Derived Cells
We have shown that CyPA has direct chemotactic effects on bone marrow-derived cells and promotes vascular cell proliferation and remodeling. 19 To determine whether cardiac CyPA promotes recruitment of bone marrow-derived cells and mediates Ang II-induced cardiac hypertrophy, GFP ϩ bone marrow cells (Ppia ϩ/ϩ ) were transplanted into irradiated Apoe Ϫ/Ϫ or Apoe Ϫ/Ϫ Ppia Ϫ/Ϫ mice. After 42 days, these chimeric mice were treated with Ang II for 4 weeks. There was no significant difference in the blood pressure between chimeric mice before and after Ang II infusion (data not shown). Ang II dramatically increased the number of bone marrow-derived cells (GFP ϩ cells) present in the cardiac tissue in the Apoe Ϫ/Ϫ recipient mice ( Figure 4C and 4E). Most significant was the accumulation of bone marrowderived cells in the perivascular area of Apoe Ϫ/Ϫ recipient mice ( Figure 4C and 4F) , which was significantly reduced in the perivascular area of Apoe Ϫ/Ϫ Ppia Ϫ/Ϫ recipient mice ( Figure 4D  and 4F ). Because many of these bone marrow-derived cells are inflammatory cells, and inflammation is associated with increased ROS, it is possible that they will contribute to the elevated ROS observed in the perivascular area.
After transplantation of Ppia ϩ/ϩ bone marrow cells to the Apoe Ϫ/Ϫ Ppia Ϫ/Ϫ mice, cardiac hypertrophy was still significantly lower in Apoe Ϫ/Ϫ Ppia Ϫ/Ϫ recipient mice compared with Apoe Ϫ/Ϫ recipient mice ( Figure 4G ). These data suggest that Ppia ϩ/ϩ inflammatory cells are not important in Ang II-induced cardiac hypertrophy. We next prepared chimeric mice transplanted with Ppia Ϫ/Ϫ bone marrow to investigate the role of recipient environment. There was no significant difference in the heart weight/BW of saline-infused groups. However, after Ang II infusion for 4 weeks, there was still a significantly greater heart weight/BW in the ApoE Ϫ/Ϫ compared with the ApoE Ϫ/Ϫ Ppia Ϫ/Ϫ chimeric mice, even after transplantation with Ppia Ϫ/Ϫ bone marrow ( Figure 4H) . These data further demonstrate that cardiac-derived CyPA, not bone marrow-derived CyPA, is most important in Ang II-induced cardiac hypertrophy.
CyPA Augments Ang II-Induced ROS Production and Proliferation in Cultured Cardiac Fibroblasts
On the basis of the above results, we next evaluated the effects of CyPA on cells present in cardiac tissue. We first studied cardiac fibroblasts because of the increase in perivascular collagen ( Figure 2B ) and the large increase in CyPA secretion (Supplemental Figure I ) in response to Ang II. We isolated cardiac fibroblasts from Apoe Ϫ/Ϫ and Apoe Ϫ/Ϫ Ppia Ϫ/Ϫ mice and measured ROS by DCF staining. In response to 1 mol/L Ang II, there was a 2-fold increase in ROS production in Apoe Ϫ/Ϫ ( Figure 5A and 5B). There was a dramatic reduction in Ang II-induced ROS production in Apoe Ϫ/Ϫ Ppia Ϫ/Ϫ fibroblasts ( Figure 5A and 5B), suggesting that CyPA plays an autocrine role in cardiac fibroblast ROS generation, similar to our findings in vascular smooth muscle cells. 11 To verify the results with DCF, we also measured ROS by lucigenin chemiluminescence. As shown in Figure 5C , Ang II-induced ROS production was significantly decreased by Ϸ50% in Apoe Ϫ/Ϫ Ppia Ϫ/Ϫ fibro- blasts compared with Apoe Ϫ/Ϫ fibroblasts, similar to results with DCF.
Excessive fibroblast proliferation induces myocardial stiffening, an important component of pathological cardiac hypertrophy. 25, 26 To evaluate whether CyPA is important in fibroblast proliferation, cell number in response to Ang II was assessed. Proliferation was significantly augmented by Ang II in Apoe Ϫ/Ϫ cardiac fibroblasts, whereas there was no change in Apoe Ϫ/Ϫ Ppia Ϫ/Ϫ fibroblasts ( Figure 5D ). These results suggest that CyPA-mediated cardiac fibroblast proliferation contributes to the perivascular cellular response.
Extracellular CyPA Promotes Proliferation and Migration of Cultured Cardiac Fibroblasts
We next evaluated the effect of extracellular CyPA on fibroblast proliferation. Interestingly, there was a small but significantly greater growth rate of Apoe Ϫ/Ϫ fibroblasts compared with Apoe
Ppia
Ϫ/Ϫ fibroblasts treated with vehicle measured by cell number ( Figure 6A ). Addition of recombinant CyPA (100 nmol/L) significantly increased proliferation of Apoe Ϫ/Ϫ fibroblasts ( Figure 6A ) and compared to Apoe Figure 6A ).
We next studied the effect of CyPA on migration of fibroblasts. There was a concentration-dependent increase in migration, which was significant at 100 nmol/L CyPA (Figure 6B) . These findings highlight the importance of extracellular and intracellular CyPA in cardiac fibroblast proliferation and migration.
Extracellular CyPA Has a Direct Effect on Cardiac Myocyte Hypertrophy
To evaluate whether CyPA could be a direct hypertrophic factor, we investigated the effect of extracellular CyPA on protein synthesis of isolated rat neonatal cardiac myocytes. Treatment with recombinant CyPA significantly increased [ 3 H]leucine incorporation in cardiac myocytes, suggesting the critical role of extracellular CyPA for the hypertrophic response ( Figure 6C ). To confirm further our data, we measured atrial natriuretic peptide and brain natriuretic peptide mRNA expression, 2 accepted markers of cardiac hypertrophy. We found that CyPA upregulated atrial natriuretic peptide and brain natriuretic peptide in neonatal cardiac myocytes ( Figure 6D ).
Cardiac fibroblasts isolated from Apoe Ϫ/Ϫ mice secreted substantial amounts of CyPA in response to Ang II (Supplemental Figure I ). Therefore, we investigated the role of fibroblast-derived secreted CyPA in mediating Ang II-induced hypertrophic response in cardiac myocytes. We treated rat neonatal cardiac myocytes with CM prepared from Ang II-stimulated cardiac fibroblasts. Protein synthesis, as measured by [ 3 H]leucine incorporation in myocytes, was used as a parameter of hypertrophy. CM prepared from Ang IIstimulated Apoe Ϫ/Ϫ fibroblasts significantly augmented [ 3 H]leucine incorporation in cardiac myocytes ( Figure 6E ). In contrast, there was no effect when myocytes were stimulated with CM prepared from the Apoe Ϫ/Ϫ Ppia Ϫ/Ϫ fibroblasts ( Figure 6E ). These results suggest that CyPA secreted from cardiac fibroblasts can act as a hypertrophic factor on cardiac myocytes. However, on the basis of these data, we cannot exclude the possibility that CyPA is involved in the secretion of another factor, either from fibroblasts or myocytes, which in turn induces cardiac hypertrophy. Together, these results indicate that both intracellular CyPA and extracellular CyPA play critical roles in the mechanisms that contribute to cardiac hypertrophy.
Discussion
The major finding of the present study is that CyPA is a novel mediator of cardiac hypertrophy. We characterized 4 important pathological mechanisms by which CyPA promotes cardiac hypertrophy (Supplemental Figure III) : (1) CyPA is a key determinant for ROS generation, (2) secretion of CyPA in the Apoe Ϫ/Ϫ background is characterized by increased oxidative stress and inflammation, (3) CyPA has a direct hypertrophic effect on cardiac myocytes, and (4) CyPA stimulates proliferation of cardiac fibroblasts that also secrete CyPA, which indirectly stimulates cardiac myocyte hypertrophy. Together, these direct and indirect effects of CyPA contribute to cardiac hypertrophy in Apoe Ϫ/Ϫ mice in response to Ang II. To examine the involvement of CyPA in the process of the cardiac hypertrophy, we used the Ang II-infusion approach, a well-established mouse model by which to study cardiac hypertrophy. Here, we observed no significant differences in the magnitude of the hypertrophy induced by Ang II between WT and Ppia Ϫ/Ϫ mice on a C57Bl/6 background. Therefore, we investigated the effect of CyPA in Apoe Ϫ/Ϫ mice because they are characterized by high ROS and inflammation. 27 We have recently shown that extracellular CyPA promotes vascular ROS production, which will further induce CyPA secretion and enhance ROS generation. 11 The fact that the CyPA effect was most apparent in the setting of Apoe deficiency supports our concept that CyPA plays a key role under conditions in which ROS production contributes to cardiac hypertrophy. However, it is also conceivable that the hyperlipidemia or heightened inflammation characteristic of this model could have contributed to the observed effects.
We anticipated that the Apoe Ϫ/Ϫ background would greatly exacerbate the CyPA-mediated hypertrophic response because Ang II-induced CyPA secretion is significantly elevated in these mice. 11 Consistent with this concept, we found that CyPA secretion from cardiac fibroblasts isolated from WT mice was dramatically lower compared with Apoe Ϫ/Ϫ fibroblasts when stimulated with Ang II.
CyPA has important roles in the immune system and is a well-described regulator of T-lymphocyte functions. 28 It is relevant to note that the primary sources of CyPA responsible for cardiac hypertrophy are likely cells in the heart and not inflammatory cells, because transplantation with Ppia ϩ/ϩ bone marrow cells still resulted in less cardiac hypertrophy in Apoe did not prevent cardiac hypertrophy in response to Ang II ( Figure 4H ). These data suggest the importance of cardiacderived CyPA for recruitment of bone marrow-derived cells to perivascular tissues to create an environment that is prohypertrophic. The interaction between cardiac myocytes and cardiac fibroblasts is a key event during Ang II-induced cardiac hypertrophy. 2, 5, 24, 29, 30 In particular, several studies have shown that cardiac myocyte hypertrophy was stimulated by growth factors and cytokines secreted from cardiac fibroblasts. [2] [3] [4] 31, 32 To prove that CyPA could be one of these factors that in a paracrine fashion ultimately induces cardiac myocyte hypertrophy, we first showed that CyPA is released from cardiac fibroblasts after Ang II treatment, and then we proved that extracellular CyPA stimulates cardiac hypertrophy. However, we cannot exclude the involvement of CyPA produced by vascular smooth muscle cells or cardiac myocytes in the enhancement of hypertrophy and fibrosis.
The precise mechanism by which CyPA directly enhances cardiac hypertrophy remains to be elucidated, in part because the CyPA receptor has not been identified. Nonetheless, the present study suggests that inhibition of CyPA may be a useful therapeutic strategy to attenuate cardiac hypertrophy in patients who experience high oxidative stresses, such as smoking, hypertension, and hyperlipidemia.
